Company / Gross Profit
Protalix BioTherapeutics, Inc. Gross Profit History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$3.6M
FY2017
5-year range
-
FY2015-FY2017
Trend
+25.6%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $0 to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2017.
Improved from $0 to $4M over the past 2 years.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2017, gross profit increased 25.6% year-over-year.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2017 | $3.6M | +25.6% |
| FY2016 | $2.9M | - |
| FY2015 | $0 | -100.0% |
As of FY2017 · SEC 10-K · Updated Jun 24, 2026